Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ETST Earth Science Tech	$0.21 +9.1%	$0.19	$0.00 ▼ $0.25	$61.80M	1.95	91,501 shs	195,149 shs
MNPR Monopar Therapeutics	$32.06 +0.7%	$37.89	$2.25 ▼ $54.30	$197.81M	1.05	26,640 shs	70,898 shs
SOPH SOPHiA GENETICS	$3.61 +4.9%	$3.31	$2.58 ▼ $4.92	$243.96M	1	91,854 shs	47,138 shs
TVRD Tvardi Therapeutics	$28.05 +5.3%	$24.97	$8.13 ▼ $34.31	$263.04M	0.21	22,521 shs	42,712 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ETST Earth Science Tech	0.00%	+2.44%	+1.45%	+50.00%	+30.43%
MNPR Monopar Therapeutics	0.00%	-10.22%	-31.52%	-9.56%	+1,142.64%
SOPH SOPHiA GENETICS	0.00%	+4.03%	0.00%	+26.67%	+4.64%
TVRD Tvardi Therapeutics	0.00%	+16.88%	+2.78%	-3.58%	+2,804,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.8948 of 5 stars	3.4	4.0	0.0	0.0	2.5	2.5	0.0
SOPH SOPHiA GENETICS	2.951 of 5 stars	3.5	5.0	0.0	0.0	2.7	0.0	0.6
TVRD Tvardi Therapeutics	1.3062 of 5 stars	3.5	0.0	0.0	0.0	1.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ETST Earth Science Tech	0.00	N/A	N/A	N/A
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	87.15% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	121.61% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	129.06% Upside

Current Analyst Ratings Breakdown

Latest ETST, TVRD, SOPH, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ETST Earth Science Tech	$33.12M	1.87	$0.01 per share	18.15	$0.01 per share	21.00
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$8.46 per share	N/A
SOPH SOPHiA GENETICS	$65.17M	3.74	N/A	N/A	$1.13 per share	3.19
TVRD Tvardi Therapeutics	$7.14M	36.85	N/A	N/A	$3.51 per share	7.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ETST Earth Science Tech	$3.25M	N/A	0.00	∞	N/A	7.93%	72.31%	41.28%	N/A
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	N/A
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	11/4/2025 (Estimated)
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-565.83%	-66.71%	N/A

Latest ETST, TVRD, SOPH, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TVRD Tvardi Therapeutics	-$0.51	-$1.00	-$0.49	-$1.00	N/A	N/A
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ETST Earth Science Tech	0.01	0.91	0.67
MNPR Monopar Therapeutics	N/A	33.93	33.93
SOPH SOPHiA GENETICS	0.62	3.39	3.21
TVRD Tvardi Therapeutics	N/A	4.04	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ETST Earth Science Tech	N/A
MNPR Monopar Therapeutics	1.83%
SOPH SOPHiA GENETICS	31.59%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
ETST Earth Science Tech	24.90%
MNPR Monopar Therapeutics	20.50%
SOPH SOPHiA GENETICS	4.88%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ETST Earth Science Tech	3	294.30 million	221.02 million	Not Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.38 million	9.09 million	N/A

ETST, TVRD, SOPH, and MNPR Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's Why

2 hours ago | marketbeat.com

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

August 21 at 11:58 AM | theglobeandmail.com

Tvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPS

August 16, 2025 | marketbeat.com

Tvardi Therapeutics expects cash to fund operations into Q4 2026

August 15, 2025 | msn.com

Tvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last year

August 15, 2025 | msn.com

Tvardi: Q2 Earnings Snapshot

August 14, 2025 | timesunion.comT

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

August 14, 2025 | finance.yahoo.com

Raymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform Recommendation

July 15, 2025 | msn.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | finance.yahoo.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | businesswire.com

Cantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight Recommendation

July 12, 2025 | msn.com

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETST, TVRD, SOPH, and MNPR Company Descriptions

Earth Science Tech OTCMKTS:ETST

$0.21 +0.02 (+9.09%)

As of 08/22/2025 03:08 PM Eastern

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Monopar Therapeutics NASDAQ:MNPR

$32.06 +0.22 (+0.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$32.06 0.00 (0.00%)

As of 08/22/2025 04:10 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

SOPHiA GENETICS NASDAQ:SOPH

$3.61 +0.17 (+4.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.60 -0.01 (-0.42%)

As of 08/22/2025 07:18 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Tvardi Therapeutics NASDAQ:TVRD

$28.05 +1.40 (+5.25%)

As of 08/22/2025 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time